Thrombocytopenia, a common complication of autologous hematopoietic stem cell transplantation (auto-HSCT) can occur immediately or later after engraftment. While various pathophysiological mechanisms may be involved, including poor hematological recovery and different infections, autoimmune thrombocytopenia has been reported only a few times and appears to be a rarity. [1] [2] [3] Hequet et al 3 reported six cases (2.0%) of autoimmune thrombocytopenia among 307 auto-HSCT cases. 3 Altered immune reconstitution after auto-HSCT may promote immunological dysregulation predisposing autoimmune disorders. However, the mechanism of autoimmune thrombocytopenia occurring after auto-HSCT is insufficiently characterized. We report a patient who developed apparent autoimmune thrombocytopenia with clonal expansion of CD8-positive T cells following autologous peripheral blood stem cell transplantation (auto-PBSCT to treat an aggressive B-cell lymphoma.
In April 2003, a 61-year-old Japanese man was diagnosed with non-Hodgkin's lymphoma of diffuse large B-cell type. The International Prognostic Index was high, that is, poor prognosis reflecting relatively advanced age, clinical stage IVb, an elevated serum lactate dehydrogenase concentration, and more than two extranodal sites involved. He had no previous history of autoimmune disease and was seronegative for HIV. After three courses of CHOP chemotherapy (cyclophosphamide 750 mg/m 2 Â 1, adriamycin 50 mg/m 2 Â 1, vincristine 1.4 mg/m 2 Â 1, and prednisolone 100 mg Â 5), the patient achieved complete remission (CR). Given the high risk of relapse and the chemosensitivity of the disease, he was considered an appropriate candidate for high-dose chemotherapy followed by auto-PBSCT. PBSC were collected after high-dose mobilization chemotherapy (etoposide 500 mg/m 2 Â 3) followed by granulocyte-colony stimulating factor (G-CSF). Nucleated cells totaling 0.35 Â 10 9 /kg, including 13.7 Â 10 6 /kg CD34-positive cells, were obtained and frozen after 2 days of apheresis, during hematologic recovery. Subsequently, three additional courses of CHOP chemotherapy were given and he remained in CR.
A complete blood count prior to transplantation showed 3.7 Â 10 9 /l white blood cells (WBC), 11.5 g/dl hemoglobin, 233 Â 10 9 /l platelets. The patient was treated with a myeloablative high-dose conditioning regimen consisting of ranimustine (200 mg/m 2 , days À8 and À3), carboplatin (300 mg/m 2 , days À7 to À4), etoposide (500 mg/m 2 , days À6 to À4), and cyclophosphamide (50 mg/kg, days À3 and À2). In October 2003 (day 0, the day of transplantation), he received thawed, unmanipulated auto-PBSC. G-CSF was administered until engraftment. He developed an episode of neutropenia and fever, requiring intravenous antimicrobial and antifungal treatment. Engraftment was prompt, with a neutrophil count of 0.5 Â 10 9 /l on day 8, and resolution of fever and platelet transfusion independence with a platelet count of 35 Â 10 9 /l on day 10. Blood counts continued to improve up to day 24, when the WBC count was 6.8 Â 10 9 /l, hemoglobin 9.2 g/dl, and platelet count 230 Â 10 9 /l. However, subsequent platelet counts gradually decreased (Figure 1 ). No evidence of bleeding or active infection was noted on physical examination, and the spleen was not palpable. In addition, no fever or localizing symptoms were present. All medication was discontinued to exclude the possibility of drug-induced thrombocytopenia, and complete blood counts and biochemical tests were repeated. A bone marrow aspirate showed a normocellular marrow with normal maturation of all hematopoietic lineages with an adequate number of megakaryocytes, and no evidence of hemophagocytosis or invasion by lymphoma cells. Serological examinations as well as polymerase-chain reaction assays to detect active viral infection, including cytomegalovirus, Epstein-Barr virus, herpes simplex virus, human herpes virus-6, and parvovirus, were negative. (Figure 1) . A follow-up Southern analysis showed a germ-line TCR. The patient was discharged to outpatient care on day 90, with a platelet count of 117 Â 10 9 /l. The patient is currently free of lymphoma 12 months after auto-PBSCT, with a stable platelet count above 100 Â 10 9 /l. Common causes of thrombocytopenia following auto-HSCT include delayed engraftment and hematopoietic recovery, various infections, drug-induced myelosuppression and relapse of disease. Several patients treated with high-dose chemotherapy followed by auto-HSCT have been reported to develop an autoimmune cytopenia as well as autoimmune syndromes such as immune thyroiditis, neurological disease, and rheumatoid arthritis. [1] [2] [3] [4] A number of previous reports have documented that regeneration of the peripheral T-cell repertoire following auto-PBSCT is derived from mature T cells either present prior to conditioning chemotherapy or included among auto-PBSC, as opposed to immature progenitor cells. 5, 6 Furthermore, thymic function may be impaired by repeated, intensive chemotherapy and radiotherapy. This process includes failure at normal checkpoints such as clonal deletion, anergy, immune deviation, and suppression, which would ordinarily control autoreactive T cells. 7 Interestingly, a recent study showed that reduction of T cells followed by compensatory expansion of remaining T-cell populations can cause autoimmune disease in mice. 8 Thus, altered immune reconstitution following auto-HSCT can result in autoimmunity causing any of several reactions including autoimmune thrombocytopenia. Our patient was found to have elevated PA-IgG and a transient increase of CD8-positive T cells with TCR rearrangement concurrently with occurrence of thrombocytopenia after engraftment of auto-PBSCT. Subsequently, thrombocytopenia spontaneously regressed, accompanied by evidence of normalization such as a relative decrease in CD8-positive T cells and disappearance of TCR rearrangement. Accordingly, we believe that a transient clonal expansion of T cells drove B cells to produce PA-IgG, and that both the T cells and the PA-IgG led to thrombocytopenia in our patient. This case may be generally informative concerning mechanisms of autoimmune disorders that complicate auto-HSCT. 
